JP2016513080A5 - - Google Patents

Info

Publication number

JP2016513080A5

JP2016513080A5 JP2015555285A JP2015555285A JP2016513080A5 JP 2016513080 A5 JP2016513080 A5 JP 2016513080A5 JP 2015555285 A JP2015555285 A JP 2015555285A JP 2015555285 A JP2015555285 A JP 2015555285A JP 2016513080 A5 JP2016513080 A5 JP 2016513080A5

Authority

JP

Japan

Prior art keywords

antibody

fragment

seq

construct

sequence

Prior art date

2014-01-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012634 fragment Substances 0.000 claims 33
• 150000003904 phospholipids Chemical class 0.000 claims 13
• 239000004074 complement inhibitor Substances 0.000 claims 11
• 102000004148 Annexin A4 Human genes 0.000 claims 9
• 108090000669 Annexin A4 Proteins 0.000 claims 9
• 229940124073 Complement inhibitor Drugs 0.000 claims 9
• 230000000295 complement effect Effects 0.000 claims 8
• 239000003795 chemical substances by application Substances 0.000 claims 5
• 230000001404 mediated effect Effects 0.000 claims 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
• OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 claims 4
• 108010009575 CD55 Antigens Proteins 0.000 claims 4
• 102000050019 Membrane Cofactor Human genes 0.000 claims 4
• 101710146216 Membrane cofactor protein Proteins 0.000 claims 4
• 230000006378 damage Effects 0.000 claims 4
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims 4
• 239000003112 inhibitor Substances 0.000 claims 4
• 108010076560 isospaglumic acid Proteins 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 4
• 230000037361 pathway Effects 0.000 claims 4
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 4
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 208000030533 eye disease Diseases 0.000 claims 3
• 208000027866 inflammatory disease Diseases 0.000 claims 3
• 210000003734 kidney Anatomy 0.000 claims 3
• 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 3
• 230000000451 tissue damage Effects 0.000 claims 3
• 231100000827 tissue damage Toxicity 0.000 claims 3
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
• RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 102100022002 CD59 glycoprotein Human genes 0.000 claims 2
• 102000016550 Complement Factor H Human genes 0.000 claims 2
• 108010053085 Complement Factor H Proteins 0.000 claims 2
• 101150018425 Cr1l gene Proteins 0.000 claims 2
• 108010069514 Cyclic Peptides Proteins 0.000 claims 2
• 102000004190 Enzymes Human genes 0.000 claims 2
• 108090000790 Enzymes Proteins 0.000 claims 2
• 208000010412 Glaucoma Diseases 0.000 claims 2
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims 2
• 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims 2
• 206010061218 Inflammation Diseases 0.000 claims 2
• 102000004856 Lectins Human genes 0.000 claims 2
• 108090001090 Lectins Proteins 0.000 claims 2
• 206010030348 Open-Angle Glaucoma Diseases 0.000 claims 2
• 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
• 229960002685 biotin Drugs 0.000 claims 2
• 235000020958 biotin Nutrition 0.000 claims 2
• 239000011616 biotin Substances 0.000 claims 2
• 239000003153 chemical reaction reagent Substances 0.000 claims 2
• 108010027437 compstatin Proteins 0.000 claims 2
• 238000001514 detection method Methods 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000011325 dry age related macular degeneration Diseases 0.000 claims 2
• 229960002224 eculizumab Drugs 0.000 claims 2
• 210000001508 eye Anatomy 0.000 claims 2
• 239000007850 fluorescent dye Substances 0.000 claims 2
• 108020001507 fusion proteins Proteins 0.000 claims 2
• 102000037865 fusion proteins Human genes 0.000 claims 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
• 230000004054 inflammatory process Effects 0.000 claims 2
• 239000002523 lectin Substances 0.000 claims 2
• 230000005291 magnetic effect Effects 0.000 claims 2
• 239000002105 nanoparticle Substances 0.000 claims 2
• 230000005298 paramagnetic effect Effects 0.000 claims 2
• 229950003203 pexelizumab Drugs 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 230000003389 potentiating effect Effects 0.000 claims 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims 2
• 206010061623 Adverse drug reaction Diseases 0.000 claims 1
• 208000023275 Autoimmune disease Diseases 0.000 claims 1
• 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims 1
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
• 208000001344 Macular Edema Diseases 0.000 claims 1
• 206010025415 Macular oedema Diseases 0.000 claims 1
• 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
• 206010038848 Retinal detachment Diseases 0.000 claims 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
• 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
• 206010052779 Transplant rejections Diseases 0.000 claims 1
• 206010046851 Uveitis Diseases 0.000 claims 1
• 206010003246 arthritis Diseases 0.000 claims 1
• 210000004556 brain Anatomy 0.000 claims 1
• 208000001763 cytomegalovirus retinitis Diseases 0.000 claims 1
• 230000001419 dependent effect Effects 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 210000002216 heart Anatomy 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 230000005764 inhibitory process Effects 0.000 claims 1
• 208000037906 ischaemic injury Diseases 0.000 claims 1
• 230000000302 ischemic effect Effects 0.000 claims 1
• 210000001503 joint Anatomy 0.000 claims 1
• 210000004185 liver Anatomy 0.000 claims 1
• 201000010230 macular retinal edema Diseases 0.000 claims 1
• 238000000034 method Methods 0.000 claims 1
• 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
• 201000002575 ocular melanoma Diseases 0.000 claims 1
• 230000003647 oxidation Effects 0.000 claims 1
• 238000007254 oxidation reaction Methods 0.000 claims 1
• 125000001095 phosphatidyl group Chemical group 0.000 claims 1
• 230000035935 pregnancy Effects 0.000 claims 1
• 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
• 230000004264 retinal detachment Effects 0.000 claims 1
• 210000000278 spinal cord Anatomy 0.000 claims 1
• 208000037816 tissue injury Diseases 0.000 claims 1
• 238000002054 transplantation Methods 0.000 claims 1
• 230000029663 wound healing Effects 0.000 claims 1